Jefferies analyst Maury Raycroft raised the firm’s price target on BioCryst (BCRX) to $15 from $14 and keeps a Buy rating on the shares following the announcement that the company will acquire Astria Therapeutics (ATXS) for $13 per share. The firm said the multiple reflects a discount likely due to crowded hereditary angioedema landscape, potential clinical/regulatory risks and FTC clearance risk. Jefferies added that Astria stockholders will own approximately 15% of pro forma equity in the combined company, which likely lowers the chance of another bidder.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- Astria Therapeutics downgraded to Hold from Buy at Jefferies
- Midday Fly By: Big banks report beats, GM takes $1.6B EV charge
- Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today
- Morning Movers: Albertsons gains, Goldman falls after quarterly results
- Video: Banks, dealmakers highlight early movers